Arthur Sands compensation by year
Nurix Therapeutics Summary Compensation Table · all 7 fiscal years held| Component | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Salary | $474,257 | $521,167 | $538,750 | $572,083 | $590,813 | $613,104 | $674,584 |
| Bonus | $400,000 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 | — | $0 | $0 | $0 |
| Option awards | $352,265 | $16,015,074 | $3,948,993 | $8,505,239 | $3,376,799 | $4,751,716 | $5,166,196 |
| Non-equity incentive | $0 | $328,100 | $297,000 | $293,250 | $355,350 | $424,350 | $510,000 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $251,512 | $3,500 | $6,723 | $45,649 | $40,158 | $23,692 | $23,358 |
| Total | $1,478,034 | $16,867,841 | $4,791,466 | $9,416,222 | $4,363,120 | $5,812,862 | $6,374,138 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Nurix Therapeutics, Inc. DEF 14A filed March 27, 2026, accession 0001140361-26-011492, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Nurix Therapeutics, Inc. filed document, accession 0001140361-26-011492. Every figure is read from that document and cited to the page and table it appears in. Filed March 27, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 337,500 | — | $17.12 |
| Option | 333,334 | — | $8.72 |
| Option | 37,334 | — | $10.83 |
| Option | 75,000 | — | $18.50 |
| Option | 12,500 | — | $18.89 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Nurix Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Nurix Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Arthur Sands · this page | President, Chief Executive Officer and Director | $6,374,138 |
| Gwenn Hansen | Chief Scientific Officer | $2,498,124 |
| Hans van Houte | Chief Financial Officer | $2,296,503 |
| Christine Ring | Chief Legal Officer and Chief Compliance Officer | $2,263,337 |
Board service
Nurix Therapeutics board · FY2021–FY2025How this board is paid
Company policy: Nurix Therapeutics pays directors a $50,000 cash retainer and $157,509 in equity. As stated in Nurix Therapeutics's FY2025 proxy.
The full Nurix Therapeutics compensation record
free company briefThis page is one person within Nurix Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Nurix Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Nurix Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Nurix Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order NRIX
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.